TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31837113
Drug: Lurasidone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40 or 80 mg/day)
Study: 22085207
Drug: One-to-one communication
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-to-one communication training with direct oral feedback from the standardized patient
Study: 17898458
Drug: 5.4 g
Normalized name: Glycerin 5.4 GM Rectal Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.4 g CLA-triacylglycerol (3.4 g as CLA) daily for 12 weeks
Study: 17898458
Drug: 10.8 g
Normalized name: GABAPENTIN 10.8 g in 10.8 g ORAL POWDER, FOR SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.8 g CLA-triacylglycerol (6.8 g as CLA) daily for 12 weeks
Study: 17898458
Drug: Placebo (10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10.8 g safflower oil) daily for 12 weeks
Study: 17898458
Drug: 5.4 g
Normalized name: Glycerin 5.4 GM Rectal Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.4 g CLA-triacylglycerol (3.4 g as CLA)
Study: 17898458
Drug: 10.8 g
Normalized name: GABAPENTIN 10.8 g in 10.8 g ORAL POWDER, FOR SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.8 g CLA-triacylglycerol (6.8 g as CLA)
Study: 17898458
Drug: Placebo (10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10.8 g safflower oil)
Study: 9443112
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 18 g/l of protein (F18)
Study: 9443112
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 13 g/l of protein (F13)
Study: 9443112
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 15 g/l of protein (F15)
Study: 2660445
Drug: Cardiospermum ointment
Normalized name: Cardiospermum halicacabum leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiospermum ointment
Study: 2660445
Drug: Ointment base
Normalized name: Ointment base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment base only (placebo)
Study: 21716127
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline nasal spray
Study: 18160462
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 microg/d for 2 years (after 1 year of treatment)
Study: 16372331
Drug: Parenteral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral estrogen or total androgen ablation
Study: 11994904
Drug: Metformin 2.5
Normalized name: glipizide-metformin 2.5 mg-250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2.5 g/day plus rosiglitazone 2 mg bd
Study: 11994904
Drug: Metformin 2.5
Normalized name: glipizide-metformin 2.5 mg-250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2.5 g/day plus rosiglitazone 4 mg bd
Study: 11994904
Drug: Metformin 2.5
Normalized name: glipizide-metformin 2.5 mg-250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2.5 g/day plus placebo
Study: 2179393
Drug: Cyclofenil treatment
Normalized name: cyclofenil
DrugBank: Cyclofenil (DB13472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclofenil treatment
Study: 6153233
Drug: Anorectic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anorectic preparation ('Trimolets'; 85 mg phenylpropanolamine per capsule)
Study: 6153233
Drug: Decongestant preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestant preparation ('Contac 500'; 50 mg phenylpropanolamine per capsule)
Study: 26857727
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment treatment for nasal carriers of S. aureus
Study: 23724544
Drug: gel with
Normalized name: GEL WITH PUMP (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel with 4,500 ppm F + 5% TMP (4,500 5% TMP)
Study: 23724544
Drug: gel with
Normalized name: GEL WITH PUMP (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel with 9,000 ppm F (9,000)
Study: 23724544
Drug: gel with
Normalized name: GEL WITH PUMP (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel with 12,300 ppm F (12,300)
Study: 23724544
Drug: gel without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gel without F or TMP (placebo)
Study: 23724544
Drug: gel with
Normalized name: GEL WITH PUMP (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel with 4,500 ppm F (4,500)
Study: 18199105
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg for 4 months
Study: 10953898
Drug: Prescription plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription plus mailed booklet
Study: 10953898
Drug: Prescription only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription only
Study: 9437624
Drug: Naltrexone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone plus brief drug counseling
Study: 8499152
Drug: Primary induction
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary induction chemotherapy with a limit of 25% tumour cell mass (TCM) reduction to separate responders from non-responders
Study: 20555312
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 25 mg equiv.
Study: 20555312
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 50 mg equiv.
Study: 20555312
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 100 mg equiv.
Study: 20555312
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (all doses)
Study: 18690985
Drug: Ceftriaxone-Vancomycin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone-Vancomycin fixed-dose combination 1.5 g B.D. for 3-10 days (Group A, n=106)
Study: 18690985
Drug: Ceftriaxone-Vancomycin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone-Vancomycin fixed-dose combination 3.0 g B.D. for 3-10 days (Group B, n=199)
Study: 18690985
Drug: Ceftriaxone-Vancomycin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone-Vancomycin fixed-dose combination
Study: 12379544
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 2 x 400 mg for 4 days and topical gentamicin and polymyxin
Study: 12379544
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and topical placebo
Study: 12379544
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin and topical antibiotics
Study: 8092089
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g raw potato starch (54% RS)
Study: 8092089
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g pregelatinized starch (0% RS)
Study: 2817915
Drug: Kenalog creams
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kenalog creams 0.025%
Study: 2817915
Drug: Aristocort creams
Normalized name: triamcinolone acetonide Topical Cream [Aristocort]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aristocort creams 0.025%
Study: 2817915
Drug: Aristocort ointments
Normalized name: triamcinolone acetonide Topical Cream [Aristocort]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aristocort ointments 0.1%
Study: 2817915
Drug: Aristocort creams
Normalized name: triamcinolone acetonide Topical Cream [Aristocort]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aristocort creams 0.5%
Study: 2817915
Drug: Hytone cream
Normalized name: hydrocortisone / iodoquinol Topical Cream [Vytone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hytone cream 1.0%
Study: 2817915
Drug: Synalar creams
Normalized name: fluocinolone Topical Cream [Synalar]
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synalar creams 0.01%
Study: 2817915
Drug: Topicort creams
Normalized name: desoximetasone Topical Cream [Topicort]
DrugBank: Desoximetasone (DB00547)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topicort creams 0.25%
Study: 2817915
Drug: Vallisone creams
Normalized name: betamethasone Topical Cream [Valisone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vallisone creams 0.1%
Study: 1215862
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of orciprenaline aerosol
Study: 21561483
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (SBC and deproteinized bovine bone)
Study: 15496274
Drug: Growth factor
Normalized name: Growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth factor priming using filgrastim (G‐CSF) and sagramostim (GM‐CSF)
Study: 15496274
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment regimens without growth factor priming
Study: 8009691
Drug: Incision, curettage,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision, curettage, and suture under antibiotic cover
Study: 54336
Drug: Standard typhoid
Normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard typhoid vaccine (lot 6A)
Study: 26400262
Drug: Protein mix
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein mix (3×20 g/d) for 4 weeks
Study: 21312265
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg/d for 52 weeks
Study: 17406745
Drug: Gene expression
Normalized name: Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene expression profile assessment for adjuvant therapy decision
Study: 17406745
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy based on gene expression profile
Study: 14756386
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg capsule from Laboratório Teuto Brasileiro Ltd.
Study: 14756386
Drug: Zoltec 150
Normalized name: Coltec EC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoltec 150 mg capsule from Laboratórios Pfizer Ltd.
Study: 8081350
Drug: Cranial electrotherapy
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial electrotherapy stimulation (CES), 45 min daily, 4 days a week for 3 weeks
Study: 8081350
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (placebo control)
Study: 782464
Drug: Prednisone plus
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone plus low-dose azathioprine and cyclophosphamide
Study: 28183580
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (propofol)
Study: 17230434
Drug: Negative binomial
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative binomial model for treatment analysis
Study: 11331840
Drug: Dacron-patch closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacron-patch closure
Study: 11331840
Drug: Vein-patch closure
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein-patch closure
Study: 29409064
Drug: Vardenafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (10 mg daily)
Study: 17162863
Drug: Tramadol (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (oral, two times a day) plus Tobradex and Diclofenac sodium eyedrops (four times a day)
Study: 10195531
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg intrathecal morphine
Study: 10195531
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (systemic morphine)
Study: 7756098
Drug: Ibuprofen, 400
Normalized name: Ibuprofen, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 400 mg three times daily for 3 days
Study: 1518268
Drug: 0.02 microM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 microM methotrexate (MTX) and 2 microM 6-mercaptopurine (6MP) combination treatment
Study: 1518268
Drug: Intravenous MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous MTX (5 g/m2)
Study: 1518268
Drug: Intravenous MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous MTX followed by 6MP (1.3 g/m2)
Study: 4053513
Drug: Intravenous vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vasopressin (1‐3 mu‐units min‐1 kg‐1)
Study: 4053513
Drug: Aspirin (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2.4 g)
Study: 4053513
Drug: Termination of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Termination of vasopressin infusion
Study: 17932223
Drug: 9-h modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-h modified release formulation of UK-338,003
Study: 17932223
Drug: 15-h modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-h modified release formulation of UK-338,003
Study: 16845959
Drug: Periodontal membrane
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periodontal membrane injection
Study: 16845959
Drug: Intrapulpal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapulpal injection
Study: 25331108
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin 1 g daily for 3 days (group A)
Study: 25331108
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (group B)
Study: 16701182
Drug: 4 paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 paravertebral injections
Study: 16701182
Drug: 1 paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 paravertebral injection
Study: 10607686
Drug: Escalating Dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating Dose Regimen (EDR)
Study: 10607686
Drug: Bulk Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk Dose Regimen (BDR)
Study: 3328638
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment by GPs (Control)
Study: 30101519
Drug: Nonablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonablative fractional laser (NAFL) treatment, 1540-nm, 40-50 mJ per microbeam, applied three times: immediately before surgery, at suture removal, and 6 weeks after surgery.
Study: 27871563
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca compartment block (FICB) with 30 mL of 0.375% ropivacaine
Study: 27871563
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (IVF) at 0.5 μg/kg body weight, repeated up to a maximum of 3 doses
Study: 22541747
Drug: Paroxetine 40
Normalized name: PARoxetine 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 40 mg tablet formulation (test product)
Study: 10553738
Drug: Clozapine 900
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine 900 mg/day
Study: 10553738
Drug: Clozapine 100
Normalized name: clozapine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 100 mg/day (Gender effect)
Study: 10553738
Drug: Clozapine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (all doses)
Study: 6240223
Drug: trimethoprim-sulfamethoxazole (160-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim-sulfamethoxazole (160-800 mg) twice daily for 10 days
Study: 26845343
Drug: QMF149 (indacaterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: QMF149 (indacaterol acetate 150 μg/mometasone furoate 320 μg)
Study: 26845343
Drug: Indacaterol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol monotherapy
Study: 26845343
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate monotherapy
Study: 18457257
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) applied topically, 9000 AU NGF in 100 ml saline solution before operation and injections every other day for one month post-operation
Study: 18457257
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with normal saline solution
Study: 15368601
Drug: rhGH (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (recombinant human growth hormone)
Study: 11248285
Drug: Tinzaparin 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 175 IU/kg subcutaneous administration
Study: 9831696
Drug: nisoldipine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: nisoldipine (20-40 mg once daily)
Study: 9831696
Drug: lisinopril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (10-20 mg once daily)
Study: 9831696
Drug: nisoldipine and
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nisoldipine and lisinopril (compared to each other)
Study: 7990347
Drug: Leukinferon administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukinferon administered intramuscularly for 10 days (day 1: 3 samples, day 2: 2 ampules, day 3: 1 ampule daily, total 1 x 10(5) U of interferon)
Study: 2524327
Drug: netilmicin 200
Normalized name: netilmicin 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: netilmicin 200 mg daily
Study: 2524327
Drug: netilmicin 200
Normalized name: netilmicin 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: netilmicin 200 mg + ampicillin 1 g daily
Study: 23541643
Drug: Dose level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level I: 69 Gy in 30 fractions of 2.3 Gy
Study: 23541643
Drug: Dose level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level II: 72 Gy in 30 fractions of 2.4 Gy
Study: 23541643
Drug: Dose level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level III: 75 Gy in 30 fractions of 2.5 Gy
Study: 19495544
Drug: Oxybutynin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin (2.5 mg) three times per day
Study: 15181050
Drug: eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eplerenone 50 mg/d
Study: 15181050
Drug: eplerenone 100
Normalized name: eplerenone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eplerenone 100 mg/d
Study: 15181050
Drug: eplerenone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: eplerenone 200 mg/d
Study: 15181050
Drug: eplerenone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: eplerenone (all doses)
Study: 9027779
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg daily, n = 24)
Study: 8391513
Drug: SCH 42495
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 42495 (200 mg, every 12 hours)
Study: 27259970
Drug: Sodium naproxen
Normalized name: Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium naproxen 550 mg b.i.d. plus rebamipide 100 mg b.i.d.
Study: 27259970
Drug: Sodium naproxen
Normalized name: Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium naproxen 550 mg b.i.d. plus placebo
Study: 20142308
Drug: R213129 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: R213129 3 mg
Study: 20142308
Drug: R213129 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: R213129 10 mg
Study: 15763574
Drug: Alcohol (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (24 g ethyl alcohol, 1508 kJ, 405 ml)
Study: 15763574
Drug: No-alcohol (867
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-alcohol (867 kJ, 405 ml)
Study: 12046033
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 mg/d for 8 weeks
Study: 11783153
Drug: Puerarin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin (600 mg intravenously, once daily for one week)
Study: 11783153
Drug: Control (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (same treatment as treated group, but without puerarin)
Study: 2109445
Drug: Pyridostigmine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 120 mg orally one hour prior to GHRH (100 micrograms iv)
Study: 2109445
Drug: GHRH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (100 micrograms iv) with pyridostigmine (120 mg)
Study: 2109445
Drug: GHRH (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (higher doses) or pyridostigmine (higher doses)
Study: 27405732
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment (CMT)
Study: 23692587
Drug: High-dose paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose paracetamol (6 grams daily for three consecutive days)
Study: 21953763
Drug: HDLI (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDLI (higher demand dose with low constant infusion)
Study: 21953763
Drug: LDHI (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDHI (lower demand dose and higher constant infusion)
Study: 18187214
Drug: Atorvastatin 10mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10mg/day
Study: 17563167
Drug: Telephone-administered supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered supportive emotion focused therapy (T-SEFT)